Related Experiment Videos
Erythromycin in the treatment of otitis media with effusion (OME)
Abstract:
Previous studies have shown erythromycin to penetrate into both the middle-ear effusion and the adenoid tissue in children with Otitis Media with Effusion (OME). The levels obtained were similar to the plasma levels. Cultures in long-standing cases of OME have yielded respiratory pathogens--Haemophilus influenzae, Streptococcus pneumoniae and Branhamella catarrhalis--in the nasopharynx in 79 per cent and in the middle-ear effusion in 18 per cent. In the present investigation a group of children with OME of more than three months' duration were given erythromycin (Abboticin) in standard dosage for the last 10 days prior to scheduled operation (paracentesis or tympanostomy). Resolution was determined as normalization of the middle ear status, and this led to cancellation of surgery. The rate of resolution--12/26 (45 per cent)--was significantly higher than in a similar group of children not treated with erythromycin--11/72 (15 per cent). There are thus rational reasons for using erythromycin in OME, in many cases as an alternative to tympanostomy.
Insights
Erythromycin treatment significantly improved middle ear status in children with Otitis Media with Effusion (OME), leading to surgery cancellation in 45% of cases. This suggests erythromycin as a viable alternative to tympanostomy for OME management.
Area of Science:
- Pediatrics
- Otolaryngology
- Pharmacology
Background:
- Otitis Media with Effusion (OME) is common in children.
- Respiratory pathogens are frequently found in OME cases.
- Erythromycin demonstrates penetration into middle ear and adenoid tissues.
Purpose of the Study:
- To evaluate the efficacy of erythromycin in resolving OME.
- To determine if erythromycin can be an alternative to surgical intervention for OME.
Main Methods:
- A prospective study involving children with OME of over three months' duration.
- Children received standard dosage erythromycin for 10 days before scheduled surgery.
- Resolution was defined as normalization of middle ear status, leading to surgery cancellation.
Main Results:
- A resolution rate of 45% (12/26) was observed in the erythromycin-treated group.
- The resolution rate in the untreated control group was 15% (11/72).
- The difference in resolution rates was statistically significant.
Conclusions:
- Erythromycin treatment shows a significantly higher resolution rate for OME compared to no treatment.
- Erythromycin offers a rational, non-surgical therapeutic option for OME in children.
- This approach may reduce the need for tympanostomy in many OME cases.